Skip to main content
Fig. 2 | BMC Cardiovascular Disorders

Fig. 2

From: The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial

Fig. 2

Representative cases of the mean amplitude of glucose excursion (MAGE) and minimum fibrous cap thickness (FCT) in the vildagliptin and control groups: a Representative case of the vildagliptin group. The MAGE was dramatically reduced from 88.1 mg/dl at baseline to 52.9 mg/dl at follow-up. Optical coherence tomography (OCT) imaging showed that the thinnest part of FCT on lipid-rich plaque was improved from 70 µm to 160 µg (lengths between white allows showing the minimum FCT). b Representative case of the control group. The MAGE was almost unchanged from 67.4 mg/dl at baseline to 59.0 mg/dl at follow-up. OCT imaging showed that the minimum FCT remained thin and virtually unchanged (90 µm at baseline and 100 µg at follow-up)

Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us